Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes.
Huselton E, Rettig MP, Fletcher T, Ritchey J, Gehrs L, McFarland K, Christ S, Eades WC, Trinkaus K, Romee R, Kulkarni S, Ghobadi A, Abboud C, Cashen AF, Stockerl-Goldstein K, Uy GL, Vij R, Westervelt P, DiPersio JF, Schroeder MA. Huselton E, et al. Leuk Lymphoma. 2021 Jun;62(6):1441-1449. doi: 10.1080/10428194.2021.1872068. Epub 2021 Jan 19. Leuk Lymphoma. 2021. PMID: 33467957 Free PMC article. Clinical Trial.
Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS.
Huselton E, Rettig MP, Campbell K, Cashen AF, DiPersio JF, Gao F, Jacoby MA, Pusic I, Romee R, Schroeder MA, Uy GL, Marcus S, Westervelt P. Huselton E, et al. Leuk Res. 2021 Nov;110:106713. doi: 10.1016/j.leukres.2021.106713. Epub 2021 Sep 22. Leuk Res. 2021. PMID: 34619434 Free PMC article. Clinical Trial.
Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide.
Eastburg L, Russler-Germain DA, DiPersio JF, Fountaine T, Andolina JR, Abboud R, Huselton E. Eastburg L, et al. Among authors: huselton e. Leuk Lymphoma. 2022 Jan;63(1):222-226. doi: 10.1080/10428194.2021.1978087. Epub 2021 Nov 18. Leuk Lymphoma. 2022. PMID: 34794373
A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma.
Schroeder MA, Fiala MA, Huselton E, Cardone MH, Jaeger S, Jean SR, Shea K, Ghobadi A, Wildes T, Stockerl-Goldstein KE, Vij R. Schroeder MA, et al. Among authors: huselton e. Clin Cancer Res. 2019 Jul 1;25(13):3776-3783. doi: 10.1158/1078-0432.CCR-18-1909. Epub 2019 Apr 5. Clin Cancer Res. 2019. PMID: 30952640 Free PMC article. Clinical Trial.
A single-arm pilot study of a mobile health exercise intervention (GO-EXCAP) in older patients with myeloid neoplasms.
Loh KP, Sanapala C, Watson EE, Jensen-Battaglia M, Janelsins MC, Klepin HD, Schnall R, Culakova E, Vertino P, Susiarjo M, Lin PJ, Mendler JH, Liesveld JL, Huselton EJ, Taberner K, Mohile SG, Mustian K. Loh KP, et al. Among authors: huselton ej. Blood Adv. 2022 Jul 12;6(13):3850-3860. doi: 10.1182/bloodadvances.2022007056. Blood Adv. 2022. PMID: 35320340 Free PMC article. Clinical Trial.
Adapting a patient-centered communication tool for older patients with acute myeloid leukemia and their oncologist.
Watson E, Sanapala C, Cortes AM, Klepin HD, Wittink M, Norton S, Richardson DR, Dale W, Magnuson A, Mendler JH, Liesveld J, Huselton E, O'Dwyer K, LeBlanc TW, El-Jawahri A, Wong ML, Loh KP. Watson E, et al. Among authors: huselton e. Blood Adv. 2022 Nov 8;6(21):5707-5710. doi: 10.1182/bloodadvances.2022008041. Blood Adv. 2022. PMID: 35930701 Free PMC article. No abstract available.
24 results